Trending

Bristol-Myers Squib

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after

X

NICE reverses stance on Celgene’s Revlimid for myeloma maintenance

https://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/

The future of real world evidence

The future of real world evidence

Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role

X

The future of real world evidence

https://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/

FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention use

FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention use

Bayer and Janssen’s novel oral anticoagulant (NOAC) Xarelto has a new string to its bow after the FDA

X

FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention use

https://pharmaphorum.com/news/fda-approves-bayer-janssens-xarelto-in-new-blood-clot-prevention-use/

Keytruda wins another first with approval based on biomarkers

Keytruda wins another first with approval based on biomarkers

For the first time, FDA approves drug on the basis of biomarkers, rather than location.

X

Keytruda wins another first with approval based on biomarkers

https://pharmaphorum.com/news/merck-cancer-biomarkers-keytruda/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com